As per the gene summary view, a total of 27 analyses comprising brain and CNS cancer, cervical cancer, esophageal cancer, leukaemia, lymphoma and prostate cancer, showed statistically significant higher IQGAP2 mRNA expression levels in tumor, while 42 analyses including bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, leukamia, lung cancer and melanoma showed reduced expression. Here, IQGAP2 is linked to prostate cancer.